Well, it is curious that several weeks after the 8-K info, we have a PR on last day of 2nd Qtr regarding the info in the filing.
What we know is that they are communicating back and forth. Having to read between the lines, it is all conjecture, but we've gotten some steady PRs, some of which deal with new elements not really previously discussed or in the Jan open letter and most of the PR news we are getting seems rather after the fact, so let's look at a few pieces:
Feb 3 PR - Filing of Patent for Activating NR2F6 Silenced CAR-T cell for solid tumors (we are 4 months down the line)
Feb 17 PR - Checkpoint inhibitor found to stimulate key immune system I-17 and I-18
Feb 24 PR - Completes Preclinical Experimentation for siRNA NR2F6 Checkpoint Inhibitor, this in cooperation with Dr. Kesari for new IND.
March 23 PR - tCellVax IND submitted which is culmination of the previous 3 PRs it seems. We are 2.5 months out from this IND filing without an update?
April 28 PR - HemaXellerate update (delayed or after the fact of new study in Mexico with positive results already known by company). So company is now delaying release of positive info for whatever reasons.
May 3 PR - 1 month data from HemaX in Mexico showing positive results reveals that April 28th PR release shows they delayed PR about the licensing of clinical trial in Mexico. (Orphan drug status applied for in Jan and we've had no update in that regard).
May 19 PR - ucVax I don't think anyone saw this coming. Universal donor development program started. Now this wasn't in Jan open letter of priorities, so it is somewhat likely that the focus to begin this development may be fruit of the Eli Lily Open Drug Development interest and/or the NCATs research or RGBP wouldn't focus funding on something that wasn't laid out a priority for the year. I.E., this may be a very promising interest partner development.
June 2 PR - Small Molecule Drug Screening Program targeting NR2F6 and using identified libraries of compounds.
June 7 PR - Hiring of Objective Capital Partners to negotiate selling, licensing or partnership developments. (I orginally thought this was in light of HemaXellerate Mexico development, but in light of the fact that they had been cooperating with Eli Lily's compound research library since Feb as someone posted, this hiring may very well be linked to one or more aspects of the NR2F6 small molecule development program and its much broader market potential, which would be very good news indeed, since the release of PRs seem to be delayed until after the facts are in.
Now the fact that an 8-K revealed the RGBP - Eli Lily program arrangements, but no PR with a PR coming out last week may or may not indicate that RGBP and Eli-Lily are close to some type of further agreement regarding research development around NR2F6, including the tCellVax IND and/or ucVax preclinical development.
The 2 PRs in succession on June 14th and June 16th about Small Molecule Drug Screening obviously tried to drive home that this was very significant news in their minds and while they didn't lay out a lot of specifics, in the context of the timing of all the previous PRs, they clearly expected a much larger market reaction.
2 weeks later, they finally release news on Eli-Lily cooperation.
That may or may not indicate we are a couple weeks away from news of some type of licensing or monetary related news. They wouldn't have hired Objective Capital Partners with a retainer and monthly payments unless one or more of the INDs and patents had significant value in their minds at this point.
So, while we don't have the hard facts, and we have curious silence on dCellVax, ODD for HemaXellerate and no update on the tCellVax IND, clearly the experiments with Kesari, NCATs and Eli-Lily have been bearing fruit and uncovering more venues of development pipeline possibilities of which we should have something more concrete I would expect sometime in this, the 3rd Qtr.
AI
